ContraFect
ContraFect is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics to combat life-threatening, drug-resistant infectious diseases. Leveraging its proprietary lysin and amurin platforms, ContraFect aims to address the urgent global challenge of antibiotic resistance by developing novel, targeted therapies that directly attack and destroy bacteria. The company’s lead product candidates are designed to treat serious infections, including those caused by Staphylococcus aureus, with the goal of improving patient outcomes where traditional antibiotics may fail. ContraFect’s commitment to advancing next-generation anti-infective therapies positions it at the forefront of efforts to address unmet medical needs in infectious disease management.
